EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

Journal of Clinical Investigation

Volumn 121, Issue 12, 2011, Pages 4712-4721

  Fukuoka, Hidenori ^a   Cooper, Odelia ^a   Ben Shlomo, Anat ^a   Mamelak, Adam ^a   Ren, Song Guang ^a   Bruyette, Dave ^b   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b VCA West Los Angeles Animal Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; PROOPIOMELANOCORTIN;

ACTH SECRETING ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCORTISOLISM; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANIMALS; CELL LINE, TUMOR; CORTICOSTERONE; DOG DISEASES; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; PITUITARY ACTH HYPERSECRETION; PRO-OPIOMELANOCORTIN; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SECRETORY RATE; TUMOR BURDEN;

EID: 84055217296     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60417     Document Type: Article

References (56)

1. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003; 112(11):1603-1618. (Pubitemid 38063716)
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006; 367(9522):1605-1617. (Pubitemid 43674231)
3. Biller BM, et al. Treatment of adrenocorticotropindependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454-2462. (Pubitemid 352008503)
4. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7(5):279-289.
5. Jehle S, Walsh JE, Freda PU, Post KD. Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93(12):4624-4632.
6. Dwyer AJ, et al. Pituitary adenomas in patients with Cushing disease: initial experience with Gd- DTPA-enhanced MR imaging. Radiology. 1987; 163(2):421-426. (Pubitemid 17068919)
7. Oldfield EH, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991;325(13):897-905.
8. Patronas N, et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin- secreting pituitary tumors. J Clin Endocrinol Metab. 2003;88(4):1565-1569. (Pubitemid 36623371)
9. Boscaro M, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115-122.
10. Pivonello R, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223-230.
11. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-3202.
12. Castillo V, et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology. 2006;147(9):4438-4444. (Pubitemid 44268395)
13. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59(2 suppl):21-26. (Pubitemid 38610223)
14. Murdoch GH, Potter E, Nicolaisen AK, Evans RM, Rosenfeld MG. Epidermal growth factor rapidly stimulates prolactin gene transcription. Nature. 1982;300(5888):192-194. (Pubitemid 12006353)
15. Fukuoka H, et al. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol. 2011;25(1):92-103.
16. Onguru O, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol. 2004;17(7):772-780. (Pubitemid 38843359)
17. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab. 1996;81(2):656-662. (Pubitemid 26055681)
18. Theodoropoulou M, et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol. 2004;183(2):385-394. (Pubitemid 39562718)
19. Kiyokawa H, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85(5):721-732.
20. Nakayama K, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85(5):707-720.
21. Fero ML, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996;85(5):733-744.
22. Roussel-Gervais A, et al. Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol. 2010;24(9):1835-1845.
23. Wang Q, Greene MI. Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest. 2008;118(7):2389-2392. (Pubitemid 351949768)
24. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
25. Mellinghoff IK, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012-2024. (Pubitemid 41609094)
26. Cohen EE, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418-8424. (Pubitemid 41746956)
27. Castillo VA, Gallelli MF. Corticotroph adenoma in the dog: pathogenesis and new therapeutic possibilities. Res Vet Sci. 2010;88(1):26-32.
28. Meij BP. Hypophysectomy as a treatment for canine and feline Cushing's disease. Vet Clin North Am Small Anim Pract. 2001;31(5):1015-1041. (Pubitemid 32861460)
29. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. (Pubitemid 38720929)
30. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004;64(20):7241-7244. (Pubitemid 39372059)
31. Kemppainen RJ, M EP. Animal models of Cushing's disease. Trends Endocrinol Metab. 1994;5(1):21-28.
32. Kovalovsky D, et al. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol. 2002;16(7):1638-1651. (Pubitemid 34746009)
33. Bousquet C, Zatelli MC, Melmed S. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immunoneuroendocrine interfacing. J Clin Invest. 2000; 106(11):1417-1425.
34. Jenks BG. Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved. Ann N Y Acad Sci. 2009;1163:17-30.
35. Poulin G, Turgeon B, Drouin J. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol. 1997;17(11):6673-6682. (Pubitemid 27451214)
36. Lamolet B, et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001;104(6):849-859. (Pubitemid 32289278)
37. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C. NF-kappaB participates in the corticotropin- releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem. 2004;279(12):10837-10840. (Pubitemid 38401572)
38. Maira M, Couture C, Le Martelot G, Pulichino AM, Bilodeau S, Drouin J. The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. J Biol Chem. 2003;278(47):46523-46532. (Pubitemid 37452225)
39. Moon DO, Kim MO, Heo MS, Lee JD, Choi YH, Kim GY. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Arch Pharm Res. 2009;32(10):1351-1360.
40. Festuccia C, et al. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer. 2005;12(4):983-998. (Pubitemid 41815791)
41. Lidhar K, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab. 1999;84(10):3823-3830. (Pubitemid 30645248)
42. Bamberger CM, et al. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol. 1999;140(3):250-255. (Pubitemid 29155584)
43. Georgitsi M, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321-3325. (Pubitemid 47236408)
44. Liu NA, et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A. 2011;108(20):8414-8419.
45. Carbajal L, Biswas A, Niswander LM, Prizant H, Hammes SR. GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Mol Endocrinol. 2011; 25(6):1055-1065.
46. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65(1):338-348. (Pubitemid 40070827)
47. Marti U, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid. 2001;11(2):137-145. (Pubitemid 32221036)
48. Xia W, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog. 2009;48(7):610-617.
49. Lo HW, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005;7(6):575-589.
50. Lin SY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3(9):802-808.
51. Wang SC, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006;8(12):1359-1368.
52. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009;28(43):3801-3813.
53. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002;8(11):1281-1287. (Pubitemid 35373561)
54. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 2008;68(15):6377-6386.
55. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, Melmed S. Heregulin regulates prolactinoma gene expression. Cancer Res. 2009;69(10):4209-4216.
56. Ben-Shlomo A, et al. Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol. 2009;23(3):337-348.